OMasahiro NISHIBORI¹, Shuji MORI²

Okayama Univ Grad Sch Med Dent & Pharm Sci, Dept Pharmacol, ²Shujitsu Univ, Sch Pharm

Recent development of molecular- targeted drugs provided the revolutionary changes in the treatment of malignant tumors and inflammatory diseases including rheumatoid arthritis. As this background, it was essential

Recent advances of molecular-targeted therapy, - overview -

MS10-1

to elucidate various exacerbation factors and abnormality of signal transduction involved in these malignant diseases. Molecular- targeted drugs are aimed to snipe at the characteristic molecule which can be called the Achilles' tendon of various diseases, thus leading to high specificity and fewer adverse effects. The development of molecular- targeted drugs started from tyrosine kinase inhibitor is linked to success of antibody therapeutics, then will lead to the next generation. In this symposium, the outline and future direction of molecular-targeted therapy will be discussed.